Another major advance vs cancer!
@ascocancer.bsky.social
#ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
ascopubs.org/doi/10.1200/...

Thank you everyone who was able to attend Friday night's dinner with our @aahpm.bsky.social Cancer Tx SIG friends. What a perfect night of connection! See you again at #ASCO26 #pallonc #supponc

@realbowtiedoc.bsky.social
@darcyburbage.bsky.social
@ascocancer.bsky.social
@crisbergerot.bsky.social

1 week left to go. Will you be there? #pallonc #supponc #ASCO26

@crisbergerot.bsky.social
@realbowtiedoc.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
@ericroeland.bsky.social
@mazietsangmd.bsky.social
@ascocancer.bsky.social
@darcyburbage.bsky.social
@rsedhom.bsky.social

I’m excited about the educational program of the upcoming #ASCO26 annual meeting! @ascocancer.bsky.social

Join us for our **Live Meeting** @ascocancer.bsky.social on Saturday May 30th 4:30-6p CST Room E253cd #ASCO26

@realbowtiedoc.bsky.social
@darcyburbage.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
@ericroeland.bsky.social

Lung Cancer Abstracts I’ll Be Watching Closely at ASCO26 - Eric Singhi

@lungoncdoc.bsky.social

oncodaily.com/voices/eric-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Looking Forward to Connecting with Colleagues at ASCO26 - Estelamari Rodriguez

@latinamd.bsky.social @herbloongmd.bsky.social @ascocancer.bsky.social

oncodaily.com/voices/estel...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

More than 75 studies led by Dana-Farber-affiliated researchers will be presented at the @ascocancer.bsky.social Annual Meeting next week, with compelling and potentially practice-changing results spanning multiple cancer types. bit.ly/4ui1kAe #ASCO26

The final study presented at #ASCO26 Plenary: RASolute-302 results show daraxonrasib meeting all primary and key secondary endpoints, demonstrating significant and clinically meaningful improvements in OS, PFS, and ORR in metastatic #PDAC: https://bit.ly/49r62n1
#ASCODailyNews

Presenting our new study at #ASCO26 right now!
Provider profits on cancer drugs have grown 4-fold to $40 billion in the last decade and a half.
@ascocancer.bsky.social @mskcancercenter.bsky.social @hannahrabrams.bsky.social @nihcm.bsky.social

Honored and Grateful to Be Selected as ASCO26 Featured Voice - Laura Alder

@lauraaldermd.bsky.social @ascocancer.bsky.social
@aakashdeeparora.bsky.social

oncodaily.com/voices/laura...

#OncoDaily #Oncology #Cancer #Health #Medicine

Dr. Wolpin gets a well-deserved standing ovation at the plenary session of #ASCO26 for this K-M curve

Hope that everyone at @ascocancer.bsky.social's #ASCO26 has a great conference!

The Heme/Onc feed is now filtering for the #ASCO26 hashtag, so don't forget to share your posts and pictures as you see incredible speakers and presentations!

Room S100bc at #ASCO26 is popping, everyone here to learn about #Melanoma and #SkinCancer: https://bit.ly/4fdLpOP

#melsm

Our FINAL #webinar for the year 😢 before #ASCO26. Join us for the amazing #DrDale and @mycarg.bsky.social cross over #pallonc #supponc #gerionc

Presenting at #ASCO26 now!
Our new study: Bribes from the drug industry can lead oncologists to use WORSE treatments (not just better ones)
@ascocancer.bsky.social @mskcancercenter.bsky.social @dusetzinas.bsky.social @commonwealthfund.org @nihcm.bsky.social @arnoldventures.bsky.social

Farewell #ARM26!
#ASCO26, see you in about 5 hours!
@ascocancer.bsky.social @academyhealth.bsky.social

🎙️ @ascocancer.bsky.social podcasts provide high quality cancer info & discussion in an accessible & enjoyable audio format! Give us a listen if you're not already a subscriber!

Proud to be featured #ASCO26 with my fellow hosts

ascopubs.org/journal/op/p...

This meeting warms my heart every year and most anticipated part of #ASCO26 for me. Can't wait to see everyone face to face instead on my screen. Join us!

⚠️ New findings presented in the plenary session at #ASCO26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer.

In our social media coverage of #ASCO26, who do you want to hear from?

1️⃣ <a href="https://poll.blue/p/UPGpRq/1" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">Abstract authors
2️⃣ <a href="https://poll.blue/p/UPGpRq/2" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">ASCO leadership
3️⃣ <a href="https://poll.blue/p/UPGpRq/3" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">Attendees
4️⃣ <a href="https://poll.blue/p/UPGpRq/4" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">Presenters and speakers

📊 Show results

Congratulations to Deb Schrag, MD, MPH, FASCO on being elected to serve as ASCO President for the 2027-2028 term! Dr. Schrag will take office as President-Elect after the #ASCO26 Annual Business Meeting.

Learn more about additional elected members: brnw.ch/21wYvyc

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://nej.md/4nWaxvM

#ASCO26

Finally, some real progress on pancreatic cancer. We heard the promising daraxonrasib top-line results last month. The details presented at #ASCO26 & in @NEJM look just as good.

(1/3) New findings from MSK researchers that will be presented at #ASCO26 this weekend found that carefully selected patients with HPV-positive #throatcancer can receive significantly less radiation while maintaining excellent outcomes.